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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
The objectives of this review are:
• To assess the diagnostic accuracy of PCT, CRP and presepsin for sepsis in adults and children.
• To investigate sources of heterogeneity in the estimates of diagnostic accuracy
• To compare the performance of the above tests.
B A C K G R O U N D
This is the protocol for the three diagnostic test accuracy reviews:
1. Procalcitonin for the diagnosis of sepsis in adults and
children;
2. C-reactive protein for the diagnosis of sepsis in adults and
children; and
3. Presepsin for the diagnosis of sepsis in adults and children.
A comparison of the three diagnostic tests will be included in the
review: Presepsin for the diagnosis of sepsis in adults and children.
Target condition being diagnosed
Sepsis, which consists of systemic inflammatory response to an
infection, is increasing in incidence (Bone 2009; Martin 2012).
There was more than a double-fold rise in the hospitalization rate,
from 11.6 to 24.0 per 10,000 population between 2000 and 2008,
for people primarily diagnosed with sepsis. This increase may be
due to increasing antimicrobial resistance, greater use of invasive
medical procedures and immunosuppressive drugs, and the in-
creasing elderly population (Martin 2012). The sepsis spectrum:
sepsis, severe sepsis and septic shock, is a leading cause of mor-
tality in critically ill people (Angus 2001). The number of deaths
from severe sepsis may be equivalent to, or surpass, those from
cancer, stroke or acute myocardial infarction (Angus 2001). The
likelihood of in-hospital mortality is at least eight times higher in
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people with sepsis than in people with other medical conditions
(Hall 2011). The average length of stay in hospital for people who
are hospitalized for sepsis is 75% longer than for those hospitalized
for other diagnoses (Hall 2011).
Early signs of sepsis are quite variable and non-specific, making the
routine diagnosis of sepsis challenging. Delay in diagnosing sepsis
further worsens the outcome in people with sepsis. The challenge
lies in the immediate and accurate distinction of sepsis from the
non-infectious systemic inflammatory response syndrome (SIRS)
whichmay occur in critically ill people. In adults, SIRS consists of a
core temperature over 38oC or lower than 36oC, a respiratory rate
over 20 breaths per minute or PCO2 (partial pressure of carbon
dioxide in the blood) below 32 mmHg, a pulse rate over 90 beats
per minute and a leucocyte count less than 4000/mm3 or more
than 12,000/mm3 or more than 10% band cells (Bone 2009). In
children, the cut-off values for the four criteria of temperature,
pulse rate/heart rate, respiratory rate and leucocyte count vary for
different age groups (Goldstein 2005). Additionally, the confir-
mation of bloodstream infections (which may arise from bacte-
rial, fungal, viral or parasitic origins) by culture, is positive in only
about 30% to 50% of sepsis cases (Murray 2012). In 1991, a con-
sensus panel of the American College of Chest Physicians (ACCP)
and the Society of Critical Care Medicine (SCCM) provided a
practical framework for the definition of sepsis (Bone 2009). The
panel defined sepsis as the presence of two or more SIRS criteria,
with documented or suspected infection. However, in 2003, an
international consensus panel of the SCCM, the European Society
of Intensive Care Medicine (ESICM), the ACCP, the American
Thoracic Society (ATS) and the Surgical Infection Society (SIS),
having noted that the SIRS criteria published in 1992 were unduly
sensitive and non-specific, provided an expanded list of variables
for the diagnosis of sepsis, severe sepsis and septic shock (Levy
2003). Despite the revised definition for sepsis, the ACCP/SCCM
definition which entails SIRS criteria may be preferred by most
clinicians, because of its concise nature.
Reports from a recent study among people with severe sepsis also
question the sensitivity of the SIRS criteria for sepsis diagnosis.
The use of the SIRS criteria for the diagnosis of sepsis would miss
out one in eight people with infection and organ failure. These
people with SIRS-negative severe sepsis have similar epidemiologic
trends to people who have the typical SIRS criteria (Kaukonen
2015).
Early in 2016, another set of updated criteria for sepsis was pro-
posed by a consensus task force of the ESCIM and the SCCM
defining sepsis as a life-threatening organ dysfunction resulting
from a dysregulated host response to inflammation. The new def-
inition recommended discarding the term severe sepsis and fo-
cused on organ dysfunction as a distinguishing point between an
infection and sepsis. It proposed a tool - quick SOFA (qSOFA)-
Sequential (sepsis-related) Organ Failure Assessment. The qSOFA
is based on the presence of two of three warning signs for the rapid
identification of organ dysfunction and people at increased risk of
mortality or prolonged stay in the intensive care unit. The three
warning signs include an altered mental status, a systolic blood
pressure of 100 mmHg or less and a respiratory rate of 22 breaths
per minute or more (Singer 2016).
These continuous changes in the definition of sepsis reflect the
challenges experienced in the diagnosis of sepsis. In order to aid
the rapid distinction of sepsis from SIRS, the use of various bio-
chemical tests has been proposed and some are in clinical use for
this purpose (Dellinger 2013).
Index test(s)
We will evaluate the diagnostic performance of three different
biochemical blood tests: Procalcitonin (PCT), C-reactive pro-
tein (CRP), and presepsin which are used as biomarkers for sep-
sis. Because we anticipate many primary studies evaluating these
biomarkers, we will present the results of these tests as three sepa-
rate reviews. Presenting these test results as three separate reviews
will also enable us to interpret and discuss the findings with suffi-
cient detail. In light of the need relevant for clinical practice, we
shall conduct and present these reviews in the following order:
PCT, CRP and presepsin.
Procalcitonin (PCT) is a precursor of the hormone calcitonin pro-
duced by the parafollicular cells of the thyroid and the neuroen-
docrine cells of the lung and the intestine. Due to its being re-
leased in response to sepsis, the PCT assay is presently in use as a
diagnostic tool for sepsis, in the USA, Europe, Australia, Asia and
in some parts of Africa (Lloyd 2012; Schneider 2007).
The PCT test quantifies PCT in serum or plasma and results are
usually available within one hour. Assays can be performed at point
of care or in the routine laboratory. Commonly-observed PCT
values in healthy individualswho are aged three days old and above,
are less than 0.05 ng/mL. While PCT levels 0.5 ng/mL to 2.0 ng/
mL may indicate sepsis, levels above 2.0 ng/mL but less than 10
ng/mL indicate a high risk for progression to organ dysfunction
(Meisner 2014; Nargis 2014). In the absence of sepsis, a rise in the
levels of PCT has been reported in people with Addisonian crises
(Schumm 2010), people undergoing conditioning treatment for
stem cell transplantation using anti-thymocyte globulin (Brodska
2009) and in people undergoing transplants administered with
pan T-cell antibody (Sabat 2001).
CRP is a plasma protein synthesized by the hepatocytes. It rises
in response to inflammation (cell injury) and various pathogens
(infection) because of its cell-membrane-binding capability which
occurs through its attachment to the phosphocholine in exposed
cell membranes during cell injury, and the phosphocholine in
the polysaccharides of pathogens present in infections (Volanakis
2001). In humans, plasma CRP levels are typically below 5 mg/
L but may rise exponentially, within a few hours, in response to
an acute inflammatory stimulus (Black 2004). The typical cut off
for CRP test is 10 mg/L and most assays have a lower limit of
sensitivity of 5 mg/L. However, plasma CRP levels may not rise
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to 10 mg/L until after 24 hours, consequently, two values more
than 10 mg/L taken 24 hours apart contend the diagnosis of sepsis
(Zecca 2009). The CRP test results are available within minutes
for the point-of-care testing (POCT) assays or within an hour for
the laboratory-based assays. The POCTassays require veryminute
volumes of blood and may be semi-quantitative, such that values
less than 10 mg/L give a negative result, ruling out sepsis. The
laboratory assays are quantitative hence, they are ideal for the serial
monitoring of patients (Vallance 1991; Zecca 2009).
Presepsin is also known as soluble CD14 subtype (sCD14-
ST). It is a glycoprotein-fragment derived from monocytes and
macrophages and produced in associationwith infections. Though
its diagnostic accuracy has not been as extensively studied as that
of CRP and PCT, a few reports have found that it may have a
better prognostic value in sepsis than PCT (Masson 2014; Ulla
2013). Presepsin assays are available as POCT or routine labora-
tory tests and are based on immunochemical methods (Okamura
2011; Shirakawa 2011). Results are available as early as 20minutes
after sample collection. Reported levels of presepsin in plasma of
healthy individuals, people with SIRS, local infection or sepsis are
several folds higher than the assay limit of quantitation (Masson
2014; Ulla 2013).
Clinical pathway
When a person has signs of systemic inflammation and a suspected
infection, blood samples and relevant body fluid samples are taken
for culture to confirm the presence of an infection. The results
become available in 24 hours to 48 hours after sample collection.
In some cases, the source of infection may be obvious, such as
some respiratory tract infections in which there may be signs of a
pneumonia on a chest radiograph; urinary tract infection where
the person may present with symptoms and signs like dysuria and
urinary frequency respectively. In other cases, the presence of pre-
disposing factors in an individual raises the suspicion for sepsis.
These factors include the presence of in-dwelling catheters ormed-
ical devices; elderly people; immunosuppression such as seen in se-
vere burns, transplant recipients, people receiving chemotherapy,
people with poorly-controlled diabetes mellitus; cellulitis; recent
surgery or invasive procedure, perforated viscus and syndromes
associated with high risk of infection such as ascending cholangitis
(Wacker 2013).
Sepsis is classified as severe when there is cardiovascular dysfunc-
tion or acute respiratory distress syndrome (ARDS) or two ormore
other acute organ dysfunctions manifested as acute kidney injury,
or acute liver failure, thrombocytopaenia or coagulopathy.Hypop-
erfusion from cardiovascular dysfunction may manifest as olig-
uria, lactic acidosis or an acute mental status alteration (Dellinger
2008).
Septic shock is severe sepsis with arterial hypotension, in spite
of adequate fluid resuscitation of 20 mL/kg crystalloid, in the
presence of perfusion abnormalities. Hypotension occurs when
the mean arterial pressure is less than 70 mmHg or the systolic
blood pressure (SBP) is less than 90 mmHg or falls by more than
40 mmHg from the baseline SBP. People receiving inotropics may
not be hypotensive (Bone 2009).
Current management guidelines recommend immediate institu-
tion of therapy once sepsis is suspected. Some of the therapeutic
measures include the administration of antimicrobials within one
hour of recognition of septic shock, the quantitative resuscitation
of patients within six hours of recognition of sepsis, and the col-
lection of samples for culture before administration of antibiotics
(Dellinger 2013).
Role of index test(s)
The diagnosis of sepsis is largely dependent on clinical judge-
ment. Early diagnosis and treatment influence the course of the
illness and patient outcome. Accurate distinction between sepsis
and SIRS is challenging, however, it is required for decision-mak-
ing as regards prompt institution of antimicrobial therapy and
subsequent continuation of such therapy.Microbiological culture,
which remains the reference laboratory test for sepsis, is rife with
shortfalls, some of which include a long turnaround time of up to
48 hours for test results and false negative results in prior antimi-
crobial therapy and with fastidious organisms. Biomarkers such as
CRP, PCT, and presepsin with rapid turnaround time, have been
proposed as adjuncts in the early diagnosis of sepsis while awaiting
culture results (Sierra 2004; Wacker 2013; Zhang 2015). They do
not serve as substitutes formicrobiological culture. AlthoughCRP,
PCT and presepsin have been studied for diagnosis of sepsis, they
are not recommended for use as independent diagnostic tools for
sepsis (Chan 2011). These biomarkers, when used in conjunction
with clinical assessment, may also guide antimicrobial therapy and
reduce unnecessary antimicrobial exposure. (Schuetz 2012).
Alternative test(s)
There are a number of other biomarkers, especially inflammatory
cytokines like interleukin 6 (IL-6), IL-8,which have beenproposed
as diagnostic tools for sepsis. These other biomarkers will not be
considered for this review. There is an on-going Cochrane Review
for the role of IL-6 in the diagnosis of sepsis (Molano Franco
2015).
Rationale
In recent years, various biomarkers such as CRP, PCT and pre-
sepsin, have been studied and are proposed as helpful diagnostic
tools for sepsis (Harbarth 2001; Rothenburger 1999; Ulla 2013).
The early distinction of sepsis fromnon-infectious conditionswith
similar clinical signs, is required for instituting a prompt and ap-
propriate intervention. This ensures a favourable patient outcome
and prevents unnecessary antibiotic usage, which is a driving force
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for antibiotic resistance. The results of CRP, PCT or presepsin as
biomarkers for sepsis are usually obtained within a shorter time
compared to the traditional laboratory test for sepsis, the blood
culture or culture of other relevant body fluids. Assaying these
biomarkers may be expensive and there is a need to objectively
review the diagnostic performance of these biomarkers in order to
determine what role each may play in the prompt and accurate
distinction of sepsis from SIRS. There is currently no Cochrane
systematic review that has evaluated the test accuracy of these
biomarkers for diagnosis of sepsis in adults and children.
O B J E C T I V E S
The objectives of this review are:
• To assess the diagnostic accuracy of PCT, CRP and
presepsin for sepsis in adults and children.
• To investigate sources of heterogeneity in the estimates of
diagnostic accuracy
• To compare the performance of the above tests.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider any study that compared PCT, CRP or presepsin
levels in participants aged 29 days and older with suspected sep-
sis, in whom the confirmation of sepsis was by clinical diagnosis
or microbiological confirmation of infection in cultures, or both.
We will exclude case histories and case control studies. We will
also exclude any cross-sectional study in which data for true pos-
itives, true negatives, false positives and false negatives cannot be
extracted.
Participants
We will include adults and children admitted to wards, intensive
care units or emergency departments with suspected sepsis, or
confirmed sepsis, or both, severe sepsis or septic shock.
We will exclude neonates as there is another ongoing Cochrane
Review specifically evaluating the use of CRP and PCT for sepsis
in neonates (Seliga-Siwecka 2015) .
We will also include reports of studies with only a subgroup of
participants eligible for inclusion.
Index tests
The index tests will be CRP, PCT and presepsin.
Target conditions
The target condition is sepsis (including severe sepsis and septic
shock) as defined by the SCCM/ESICM/ACCP/ATS/SIS criteria
(Levy 2003). These criteria are listed in Appendix 1.
Reference standards
The reference standard for the diagnosis of sepsis is the criteria de-
veloped by the International Sepsis Definitions Conference (Levy
2003), and these are listed in Appendix 1. These criteria include
the presence of an infection in association with other variables.
The clinical suspicion of infection is as a result of certain charac-
teristics: perforated viscus, white blood cells in a normally sterile
body fluid, radiographic features of pneumonia with production
of purulent sputum and syndromes associated with a high risk of
infection such as ascending cholangitis (Wacker 2013). Microbio-
logical confirmation of infection involves the use of blood culture
or culture of other body fluids, it is strictly a laboratory-based test
to detect the presence of micro-organisms in blood or body fluids.
We anticipate a lot of differences in the definition used for sepsis
in the primary studies. We would include all studies that meet
any of the criteria or definitions for sepsis and perform a subgroup
analysis based on the reference standard definition.
Search methods for identification of studies
Electronic searches
We will search MEDLINE (OvidSP, 1946 to Present); EMBASE
(OvidSP, 1974 to Present); LILACS (1982 to Present); CINAHL
(1981 to Present); BIOSIS Previews (1969 to Present).
We will use an electronic search strategy that combines indexing
terms and text words to capture the index tests and the target
condition.
The current version of our search strategy forMEDLINE is shown
in Appendix 2 and was developed by Cochrane Anaesthesia, Crit-
ical and Emergency Care’s Information Specialist. We shall adapt
this strategy to the other listed databases and we will consider ar-
ticles in all languages.
We will scan TheWorld Health Organization International Clini-
cal Trials Registry Platform (WHOICTRP) and ClinicalTrials.gov
for ongoing and unpublished studies.
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Searching other resources
To identify additional studies we will use Scopus to search for
references and citations of included studies and relevant reviews.
When necessary we will contact study authors for additional in-
formation.
Data collection and analysis
Two review authors (CPO and CIO) will independently apply the
selection criteria to all titles and abstracts.
Selection of studies
We will consider studies published in all languages. We (CPO and
CIO) will retrieve the full text of all relevant articles and indepen-
dently assess for inclusion. One review author (EAO) will adjudi-
cate any case of discrepancy between CPO and CIO, concerning
the inclusion of a report. When there are multiple reports or there
is a possibility of overlapping study populations, we will select the
most recent and complete report for a study.
Data extraction and management
We will use a separate data extraction form for each index test (
PCT, CRP and Presepsin; results of each test will be presented as a
separate systematic review). Two review authors (CPO and CIO)
will use a standardized form to independently abstract information
from each study meeting the inclusion criteria. For any study in
which a subgroup of participants meets the inclusion criteria for
the review, we will extract and analyse data for this subgroup only.
If data are available, we will construct two-by-two tables for each
index test evaluated in the study at all the reported test thresholds.
Otherwise, we will compute the number of true positives, true
negatives, false positives and false negatives using the summary
estimates of sensitivity and specificity of the index test, if available.
Where reported, we will exclude any indefinite or undetermined
index test results from the analyses.
Table 1 presents the data to be extracted from each study.
We will resolve any disparities in the data extraction by consensus.
Where this fails, we will consult the third review author (EAO)
for adjudication.
Assessment of methodological quality
Two review authors (CPO and CIO) will independently assess
the methodological quality of all studies based on the Quality
Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool
(Whiting 2011). In order to ensure consistent assessments, we
have developed a rating guideline with criteria for answering sig-
nalling questions and assessing risk of bias and concerns regard-
ing applicability. This is presented in Appendix 3. We (CPO and
CIO) will pilot our review-tailored QUADAS-2 tool against 10
primary studies to assess how consistent it is and to detect any pos-
sible areas of discrepancy between review authors. If necessary, we
will make amendments to the tool to ensure consistency. We will
resolve all discordant assessments by discussion or, where neces-
sary, adjudication by a third review author (EAO).We will present
the outcome of the methodological quality assessment in tabular
form, summarizing the number of studies with low, high or un-
clear risk of bias for each of the four domains in our QUADAS-2
rating guideline. We will present concerns regarding applicability
in a similar tabular form. We will explore the influence of risk of
bias on accuracy in sensitivity analyses by excluding studies with
a high risk of bias.
Statistical analysis and data synthesis
We will first descriptively present the results of sensitivity and
specificity (and their 95% confidence intervals (CI) graphically
in both forest plots and receiver-operating characteristics (ROC)
space using the software ReviewManager 5 (RevMan 5) (RevMan
2014).
For each test, we will identify the most commonly reported test
threshold in all included studies and use the bivariate random-
effects model to perform the overall meta-analysis at that thresh-
old (Macaskill 2010). For example, commonly used thresholds
include; for CRP (10 mg/L for most assays or a lower limit of
sensitivity of 5 mg/L and above) and for PCT (general cut-off for
sepsis is 0.5 ng/mL, levels as low as 0.05 ng/mL may occur in viral
infections (Lloyd 2012; Zecca 2009). Should multiple thresholds
be reported by each study, we will perform meta-analyses at the
commonly used thresholds for each test using the bivariate ran-
dom-effects model.
Where data are sufficient we shall compare the results of the tests
directly (tests applied to the same individual) and indirectly. To
facilitate these comparisons, we shall include the covariate test
type as a covariate in the bivariate model and check the effects on
sensitivity and specificity. We will conduct and present direct and
indirect comparisons in the last systematic review we shall present,
that is, on presepsin.
We shall conduct these analyses with the statistical software SAS,
version 9.4 (sas.com/en_gb/software/sas9.html). The unit of anal-
ysis will be individual participants.
Investigations of heterogeneity
If sufficient data are available we will investigate the following
sources of heterogeneity in the diagnostic performance across stud-
ies; severity of illness (e.g. severe sepsis versus septic shock), age
(children versus adults), admission category (medical versus sur-
gical patients), test manufacturer, type of assay and reference stan-
dard by fitting the covariates in the bivariate model. Studies that
do not present criteria or stratified results for the covariates age
(children versus adults) and severity of illness (severe sepsis versus
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septic shock) will not be included in the models. Such unclear
information from the studies will be labelled not reported.
Sensitivity analyses
Wewill perform a sensitivity analysis to check robustness of the re-
sults by excluding studies with high risk of bias for eachQUADAS-
2 domain; patient selection, index test, reference standard and pa-
tient flow (Whiting 2011).
Assessment of reporting bias
Wewill not attempt to carry out any formal assessment of reporting
bias because methods for diagnostic test accuracy (DTA) reviews
have still not been conclusively recommended (Macaskill 2010).
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A D D I T I O N A L T A B L E S
Table 1. Data from each study
Study ID First author, year of publication
Type of study Journal article or unpublished study
Clinical features and settings • Presenting signs and symptoms
• Medical or surgical
• Age range for inclusion
• Intensive care unit, wards or emergency department
• Single or multi-centre study
Participants • Sample size (n)
• Country of study
• Age distribution
• Empirical antibiotics usage
Study design • Retrospective or prospective design
• Sample (consecutive, random or unclear)
Reference standard • Clinical diagnosis
• Culture - blood, body fluid
• Culture and clinical diagnosis
• Interval between index test and reference standard
Index tests • Name of assays
• Manufacturer
• Analyser/device
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Table 1. Data from each study (Continued)
• Specimen type (venous/capillary; whole blood, serum or plasma)
• Specimen tube (for laboratory-based assay)
• Cut-off values
Target Condition Sepsis spectrum - sepsis, severe sepsis, septic shock
Data • Number of true positives, false positives, true negatives, false negatives and undetermined/
uninterpretable results
• Sensitivity and specificity of index test
• Missing results for index test
• Missing results for reference standard
Notes Source of funding (whether any author is affiliated with the manufacturer of the index test; the study
was directly funded by the manufacturer; study authors reported conflicts of interests related to the
manufacturer or other funding sources)
Anything else of relevance
CRP: C-reactive protein
n: sample size
PCT: Procalcitonin
A P P E N D I C E S
Appendix 1. Criteria for sepsis diagnosis
Diagnostic criteria for sepsisa
Sepsis - documented or suspected infection in association with some of the following parameters
General parameters
• Fever (core temperature, > 38.3°C)b
• Hypothermia (core temperature, < 36°C)b
• Elevated heart rate (> 90 beats per min or > 2 SD above the upper limit of the normal range for age)
• Tachypnoea
• Altered mental status
• Substantial oedema or positive fluid balance (> 20 mL/kg of body weight over 24 h)
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Inflammatory parameters
• Leukocytosis (white-cell count, > 12,000/mm3)
• Leukopaenia (white-cell count, < 4000/mm3)
• Normal white-cell count with > 10% immature forms
Haemodynamic parameters
• Arterial hypotension (systolic pressure, < 90 mmHg; mean arterial pressure, < 70 mm Hg; or decrease in systolic pressure of > 40
mmHg in adults or to >2 SD below the lower limit of the normal range for age)
• Elevated mixed venous oxygen saturation (> 70%)c
• Elevated cardiac index (> 3.5 L/min/m2 of body surface area) d
Organ dysfunction parameters
• Arterial hypoxaemia (ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, < 300)
• Acute oliguria (urine output, < 0.5 mL/kg/h or 45 mL/h for at least 2 h)
• Increase in creatinine level of > 0.5 mg/dL (> 44 µmoL/L)
• Coagulation abnormalities (international normalised ratio, > 1.5; or activated partial-thromboplastin time, > 60 s)
• Paralytic ileus (absence of bowel sounds)
• Thrombocytopaenia (platelet count, <100,000/mm3)
• Hyperbilirubinaemia (plasma total bilirubin, > 4 mg/dL (68 µmoL/L))
Tissue-perfusion parameters
• Hyperlactataemia (> 3 mmoL/L)
• Decreased capillary refill or mottling
aAdapted from Levy 2003.
bIn children, diagnostic criteria for sepsis are signs and symptoms of inflammation plus infection with hyperthermia or hypothermia
(rectal temperature, > 38.5°C or < 35°C, respectively), tachycardia (may be absent with hypothermia), and at least one of the following
indications of altered organ function: altered mental status, hypoxaemia, increased serum lactate level, or bounding pulses.
cIn children, normal values are 75%-80%, therefore values above 70% should not be used as a sign of sepsis in children.
dNormal paediatric values are 3.5-5.5 hence values above 3.5 should not be used as a sign of sepsis in children.
Appendix 2. MEDLINE search strategy via Ovid platform
1 exp Bacteremia/ or exp Sepsis/ or exp Shock, Septic/ or exp Systemic Inflammatory Response Syndrome/ or Critical Illness/ or (sepsis
or septic* or bacter?em* or septic?em* or SIRS or Inflammatory Response Syndrome* or ((critical* or severe) adj3 (ill* or disease*)) or
(bacteria* adj6 infect* adj6 (blood* or serum or invas* or severe or systemic))).ti,ab. or Bacterial Infections/bl [Blood] (290853)
2 exp C-Reactive Protein/ or (C reactive protein* or CRP or procalcitonin or PCT or presepsin or Soluble CD14 or sCD14 or sCD
14).af. (76457)
3 1 and 2 (6609)
4 3 not (exp animals/ not humans.sh.) (6387)
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Appendix 3. QUADAS-2 rating guideline
Domain 1. Patient selection
Signaling questions and answering guidelines
1. Was a consecutive or a random sample of patients enrolled?
Answer ‘yes’ if one of the following conditions are met:
a) It is explicitly stated in the study that enrolment was consecutive (or random)
b) It is reported that all eligible, potential study participant were included and enrolment took place at all hours in any day during the
enrolment period.
Answer ‘no’ if neither of the conditions is met.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
2. Was a case-control design avoided?
This question is irrelevant because the answer will always be ‘yes’, since case-control studies are excluded from the review. It raises no
concern for bias.
3. Did the study avoid inappropriate exclusions?
Answer ‘yes’ if the stated inclusion and exclusion criteria are clear and appropriate
Answer ‘no’ if the stated inclusion and exclusion criteria include inappropriate subjects.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’
Guidelines for assessing risk of bias
Risk of bias from patient selection will be assessed as ‘low’ when signalling questions 1 and 3 are answered ‘yes’.
Risk will be assessed as ‘high’ when signalling questions 1, or 3 are answered ‘no’.
Risk will be assessed as ‘unclear’ when insufficient information is reported to answer signalling question 1 or 3.
Guidelines for assessing concern regarding applicability
Are there concerns that the included participants do not match the review question?
Answer ’low concern’ if the included participants in the study match our study question.
Answer ’high concern’ if the included participants do not match our study question.
Answer ’unclear’ if there is insufficient information to make a judgement.
Domain 2. Index test
Signaling question and answering guidelines
1. Were the index test results interpreted without knowledge of the results of the reference standard?
Answer ‘yes’ if it is stated in the study report that the index test was interpreted by an individual who was kept unaware of the result(s)
of the reference standard.
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Answer ‘no’ if it is stated that the same individual who performed the index test also applied the reference standard, or that the results
of the index test were known by the individual performing the reference standard.
Answer ‘unclear’ if there is insufficient information to answer ‘yes’ or ‘no’.
2. If a threshold was used, was it pre-specified?
Answer ‘yes’ if a pre-specified positivity threshold is stated for the index test.
Answer ‘no’ if a threshold was not pre-specified.
Answer ‘unclear’ if there is insufficient information available to answer ‘yes’ or ‘no’.
Guidelines for assessing risk of bias
Risk of bias from index test execution will be assessed as ‘low’ when signalling questions 1 and 2 are answered ‘yes’.
Risk will be assessed as ‘high’ when signalling question 1 or 2 is answered ‘no’.
Risk will be assessed as ‘unclear’ if there is insufficient information to answer signalling questions 1 or 2.
Guidelines for assessing concern regarding applicability
The index test should be described in sufficient detail to allow for replication.
Concern regarding applicability in relation to the execution of the index test will be assessed as ‘low’ if one of the following two
conditions is in place:
1. The assay for the index test is consistent with the most widely performed assays for the index test, as determined from included
studies.
2. The following details are provided for any non-standardised assay for an index test:
a) Name of manufacturer of index test
b) Instrument/analyser utilised for the assay
c) Type of specimen used for testing (venous/capillary, whole blood/plasma or serum)
d) Type of test (laboratory-based or point-of-care)
e) Type of specimen tube (for a laboratory-based assay)
Concern will be assessed as ‘high’ if none of the two conditions listed above is met.
Concern will be assessed as ‘unclear’ if insufficient information is available to make a judgement.
Domain 3. Reference standard
Signaling questions and answering guidelines
1. Is the reference standard likely to correctly classify the target condition?
Answer ‘yes’ if the diagnosis of sepsis is based on the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘no’ if the diagnosis of sepsis is not based on the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘unclear’ if there is insufficient information to answer ‘yes’ or ‘no’.
2. Were the reference standard results interpreted without knowledge of the results of the index test?
Answer ‘yes’ if the following relevant conditions are met:
a) The clinical staff making the diagnosis are kept unaware of the results of the index test
b) The radiologist interpreting the chest radiographs (in the case of a respiratory infection) was kept unaware of the results of the index
test.
c) The microbiologist interpreting culture results (in case of blood/body fluid culture) was kept unaware of the results of the index test.
Answer ‘no’ if one of the relevant conditions stated above are not met.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
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Guidelines for assessing risk of bias
Risk of bias related to the reference standard will be assessed as ‘low’ when signalling questions 1 and 2 are answered ‘yes’.
Risk will be assessed as ‘high’ when signalling question 1 or 2 is answered ‘no’.
Risk will be assessed as ‘unclear’ when insufficient information is available to answer signalling questions 1 or 2.
Guidelines for assessing concern regarding applicability
Concern that the target condition as defined by the reference standard does not match the review question, will be assessed as ‘low’ if
the target condition is sepsis diagnosed by the SCCM/ESICM/ACCP/ATS/SIS criteria.
Concern will be assessed as ‘high’ if it is not clearly stated that the target condition is sepsis diagnosed by the SCCM/ESICM/ACCP/
ATS/SIS criteria.
Concern will be assessed as ‘unclear’ if insufficient information is available to make a judgement.
Domain 4. Flow and timing
Signaling questions and answering guidelines
1. Did all participants receive a reference standard?
Answer ‘yes’ if at least 95% of included participants diagnosed using the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘no’ if less than 95% of participants were diagnosed using the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
2. Did all the participants receive the same reference standard?
Answer ‘yes’ if at least 95% of included participants diagnosed using the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘no’ if less than 95% of participants were diagnosed using the SCCM/ESICM/ACCP/ATS/SIS criteria for sepsis.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
3. Were all participants included in the analysis?
Answer ‘yes’ if the analysis encompassed all included participants; or if 5% or less are excluded from the analysis due to unavailability
of reference standard assessment.
Answer ‘no’ if the above requirement is unmet.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
4. Was there an appropriate interval between index test and reference standard?
Answer ‘yes’ if the index tests are performed on samples collected at the same time SCCM/ESICM/ACCP/ATS/SIS criteria is applied
on the participant.
Answer ‘no’ if the above requirement is unmet.
Answer ‘unclear’ if insufficient information is available to answer ‘yes’ or ‘no’.
Guidelines for assessing risk of bias
Risk of bias related to participant flow and timing will be assessed as ‘low’ when the four signalling questions are answered ‘yes’.
Risk will be assessed as ‘high’ when any of the questions is answered ‘no’.
Risk will be assessed as ‘unclear’ when insufficient information is reported to answer any one of the four signalling questions.
Footnotes
ACCP: American College of Chest Physicians
ATS: American Thoracic Society
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CRP: C-reactive protein
ESICM: European Society of Intensive Care Medicine
PCT: Procalcitonin
SCCM: Society of Critical Care Medicine
SIS: Surgical Infection Society
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